Navigation Links
Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive

NEW YORK, Oct. 6, 2011 /PRNewswire/ -- Avista Capital Partners, a leading private equity firm, today announced that it has hired Hakan Bjorklund, the departing Chief Executive Officer of Nycomed, as Healthcare Operating Executive.  Mr. Bjorklund worked closely with Avista on the development of Nycomed during Avista's ownership of the company, which was recently sold to Takeda Pharmaceuticals Company Limited for Euro 9.6 billion.

Under Mr. Bjorklund's leadership, Nycomed was transformed from a predominantly Scandinavian business into a global pharmaceutical company with leading market positions in Europe, Russia/CIS, Brazil and Latin America.  In 2006, Mr. Bjorklund led the integration of Altana Pharmaceutical, a German-based company that Nycomed purchased for Euro 4.2 billion. He was also instrumental in growing Nycomed in emerging markets, most recently through the acquisition of Guangdong Techpool Bio-Pharma Co., Ltd, a fast growing Chinese bio-pharmaceutical company, in 2010.    

Thompson Dean, Co-Managing Partner and Chief Executive Officer of Avista, said, "We are delighted to welcome Hakan to Avista.  One of the top pharmaceutical executives in Europe, he possesses a deep understanding of the global healthcare market.  Having worked closely with him for many years, I know that Hakan will bring extensive strategic, operational and investment expertise to Avista as well as strong relationships throughout the global healthcare sector."    

Newton Aguiar, the partner in charge of Avista's European operations, added, "We are looking forward to working with Hakan on healthcare investments both in Europe and throughout the world.  Hakan built Nycomed into one of the fastest growing global pharmaceutical companies, in part, by expanding its presence in key emerging markets, particularly in Russia/CIS and Latin America.  His experience will be invaluable to the healthcare management teams in Avista's portfolio as they seek to grow their own businesses."    

Mr. Bjorklund said, "This is a very exciting opportunity. Avista is a leading private equity healthcare investor with a long track record of successful investments in the pharmaceutical, medical device, and healthcare services sectors.  As CEO of Nycomed, I was deeply impressed by the sector expertise and supportive ownership philosophy that Avista brings to its investments.  I am looking forward to helping other leading healthcare companies reach their full potential as a member of the Avista team."

Before joining Nycomed, Mr. Bjorklund was Regional Director at Astra (now AstraZeneca) and, earlier, President of Astra Draco.  He is a member of the Board of Directors of Coloplast A/S, Lundbeck A/S, and Atos Medical AB. He was also a director at Danisco A/S until its recent acquisition by Dupont.  He holds a Ph.D. in Neuroscience from Karolinska Institutet in Sweden.

In addition to Nycomed, Avista's portfolio of healthcare companies includes INC Research, a leading clinical research organization; ConvaTec, a global leader in ostomy and wound care; Lantheus, a leader in diagnostic imaging; Navilyst Medical, a manufacturer and distributor of single-use fluid management and venous-access medical devices; BioReliance, a leading contract services provider focused on biological safety testing, toxicology, viral manufacturing, and laboratory animal diagnostic services; and VWR International, a leading global distributor of equipment and consumable supplies to the laboratory sector across all industries.  In addition, during its time at DLJ Merchant Banking Partners, the Avista team was significantly involved in a variety of healthcare investments, including medical device companies such as Accellent and Kinetic Concepts; healthcare services companies such as Focus Diagnostics, Charles River Laboratories, and Fisher Scientific International; and pharmaceutical companies such as Warner Chilcott and Prometheus Laboratories.

About Avista Capital Partners

Avista Capital Partners is a leading private equity firm with offices in New York, Houston, and London. Avista's strategy is to make controlling or influential minority investments in growth-oriented energy, healthcare, media, industrial and consumer businesses. Through its team of seasoned investment professionals and industry experts, Avista seeks to partner with exceptional management teams to invest in and add value to well-positioned businesses. For more information visit  


Melissa Sheer or James David
Kekst and Company

SOURCE Avista Capital Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ARAMARK Agrees to Sell its Galls Business to CI Capital Partners
2. Medical Alarm Concepts Receives Growth Capital Injection and Commitment for Future Funding
3. K-V Pharmaceutical Company to Present at Imperial Capitals 5th Annual Global Opportunities Conference
4. Water Street Healthcare Partners Completes Sale and Recapitalization of CareCentrix
5. Thoratec Presentation at Lazard Capital Markets Circulatory Assist Device Day to be Webcast
6. HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day
7. HealthTech Capital Announces Two New Investments in the Emerging HealthTech Market
8. Main Street Capital Announces New Portfolio Investment
9. MGT Capital Investments, Inc.s Plan of Compliance Accepted by NYSE AMEX, LLC
10. CVS Caremark Corporation Announces Receipt of Requisite Consents, Termination of Replacement Capital Covenant and Expiration of Consent Solicitation Relating to its 6.125% Senior Notes due August 15, 2016 (CUSIP NO. 126650BE9)
11. MGT Capital Investments, Inc. Provides Update on Recent Developments
Post Your Comments:
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/27/2016)... NY (PRWEB) , ... June 27, 2016 , ... ... using cutting edge technology to revolutionize the emergency ambulance transport experience for the ... are aware of how Uber has disrupted the taxi industry through the use ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
Breaking Medicine News(10 mins):